Recent cerebrospinal fluid biomarker studies of Alzheimers disease

Expert Review of Proteomics

Volumn 7, Issue 6, 2010, Pages 919-929

  Choi, Yong Seok ^a   Choe, Leila H ^a   Lee, Kelvin H ^a  

^a University of Delaware   (United States)

Author keywords

Alzheimers disease; biomarker; cerebrospinal fluid; mass spectrometry; proteomics

Indexed keywords

AMYLOID BETA PROTEIN; BIOLOGICAL MARKER; TAU PROTEIN;

ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; BRAIN CORTEX; CEREBROSPINAL FLUID ANALYSIS; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; ELECTROSPRAY; FRONTOTEMPORAL DEMENTIA; HUMAN; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MEDICAL RESEARCH; NEUROFIBRILLARY TANGLE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN EXPRESSION; PROTEOMICS; REVIEW; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TWO DIMENSIONAL GEL ELECTROPHORESIS; VALIDATION STUDY;

EID: 78650471118     PISSN: 14789450     EISSN: 17448387     Source Type: Journal    
DOI: 10.1586/epr.10.75     Document Type: Review

References (59)

1. Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. Alzheimers disease in the US population: prevalence estimates using the 2000 census. Arch. Neurol. 60, 1119-1122 (2003). (Pubitemid 36975801)
2. Plassman BL, Langa KM, Fisher GG et al. Prevalence of dementia in the United States: the aging, demographics, and memory study. Neuroepidemiology 29, 25-132 (2007).
3. Doody RS, Stevens JC, Beck C et al. Practice parameter: management of dementia (an evidence-based review). Neurology 56, 1154-1166 (2001).
4. Gifford DR, Cummings JL. Evaluating dementia screening tests: methodologic standards to rate their performance. Neurology 52, 224-227 (1999).
5. Knopman DS, DeKosky ST, Cummings JL et al. Practice parameter: diagnosis of dementia (an evidence-based review) - report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 56, 1143-1153 (2001). (Pubitemid 32405708)
6. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 69, 89-95 (2001).
7. Blennow K, Vanmechelen E, Hampel H. CSF total tau, Ab42 and phosphorylated tau protein as biomarkers for Alzheimers disease. Mol. Neurobiol. 24, 87-97 (2001). (Pubitemid 34066679)
8. Blennow K, Hampel H. CSF markers for incipient Alzheimers disease. Lancet Neurol. 2, 605-613 (2003). (Pubitemid 37162569)
9. Hampel H, Mitchell A, Blennow K et al. Core biological marker candidates of Alzheimers disease - perspectives for diagnosis, prediction of outcome and reflection of biological activity. J. Neural Transm. 111, 247-272 (2004). (Pubitemid 38316604)
10. Galasko D. Biomarkers for Alzheimers disease - clinical needs and application. J. Alzheimers Dis. 8, 339-346 (2005).
11. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrosinal fluid and plasma biomarkers in Alzheimer disease. Nat. Rev. Neurol. 6, 131-144 (2010).
12. Romeo MJ, Espina V, Lowenthal M et al. CSF proteome: a protein repository for potential biomarker identification. Expert Rev. Proteomics 2, 57-70 (2005). (Pubitemid 40292580)
13. Rohlff C. Proteomics in molecular medicine: applications in central nervous systems disorders. Electrophoresis 21, 1227-1234 (2000). (Pubitemid 30230787)
14. Paulson GW, Stickney D. Cerebrospinal fluid after death. Confin. Neurol. 33, 149-162 (1971).
15. Lescuyer P, Allard L, Zimmermann-Ivol CG et al. Identification of post-mortem cerebrospinal fluid proteins as potential biomarkers of ischemia and neurodegeneration. Proteomics 4, 2234-2241 (2004). (Pubitemid 39025323)
16. Finehout EJ, Franck Z, Relkin N, Lee KH. Proteomic analysis of cerebrospinal fluid changes related to postmortem interval. Clin. Chem. 52, 1906-1913 (2006). (Pubitemid 44470698)
17. You JS, Gelfanova V, Knierman MD, Witzmann FA, Wang M, Hale JE. The impact of blood contamination on the proteome of cerebrospinal fluid. Proteomics 5, 290-296 (2005). (Pubitemid 40189659)
18. Omenn GS. The Human Proteome Organization Plasma Proteome Project pilot phase: reference specimens, technology platform comparisons, and standardized data submissions and analyses. Proteomics 4(5), 1235-1240 (2004).
19. Zhang J, Goodlett DR, Peskind ER et al. Quantitative proteomic analysis of age-related changes in human cerebrospinal fluid. Neurobiol. Aging 26, 207-227 (2005). (Pubitemid 39610462)
20. Ogata Y, Charlesworth C, Higgins L, Keegan BM, Vernino S, Muddiman DC. Differential protein expression in male and female human lumbar cerebrospinal fluid using iTRAQ reagents after abundant protein depletion. Proteomics 7, 3726-3734 (2007). (Pubitemid 350022278)
21. Yuan X, Desiderio DM. Proteomics analysis of prefractionated human lumbar cerebrospinal fluid. Proteomics 5, 541-550 (2005). (Pubitemid 40262071)
22. Bischoff R, Luider TM. Methodological advances in the discovery of protein and peptide disease markers. J. Chromatogr. B 803, 27-40 (2004). (Pubitemid 38340636)
23. Hu Y, Malone JP, Fagan AM, Townsend RR, Holtzman DM. Comparative proteomic analysis of intra-and interindividual variation in human cerebrospinal fluid. Mol. Cell. Proteomics 4, 2000-2009 (2005). (Pubitemid 41830194)
24. Castano EM, Roher AE, Esh CL, Kokjohn TA, Beach T. Comparative proteomics of cerebrospinal fluid in neuropathologically-confirmed Alzheimers disease and non-demented elderly subjects. Neurol. Res. 28, 155-163 (2006).
25. Hu Y, Hossein A, Kauwe JSK et al. Identification and validation of novel CSF biomarkers for early stages of Alzheimers disease. Proteomics Clin. Appl. 1, 1373-1384 (2007).
26. Sihlbom C, Davidsson P, Sjogren M, Wahlund LO, Nilsson CL. Structural and quantitative comparison of cerebrospinal fluid glycoproteins in Alzheimers disease patients and healthy individuals. Neurochem. Res. 33, 1332-1340 (2008).
27. Kazanis K, Dalamaga M, Nounopoulos C et al. Ischemia modified albumin, high-sensitivity C-reactive protein and natriuretic peptide in patients with coronary atherosclerosis. Clin. Chim. Acta 408, 65-69 (2009).
28. Lopez JL. Two-dimensional electrophoresis in proteome expression analysis. J. Chromatogr. B 849, 190-202 (2007). (Pubitemid 46529329)
29. Chen EI, Yates III JR. Cancer proteomics by quantitative shotgun proteomics. Mol. Oncol. 1, 144-159 (2007).
30. Siuzdak G. The Expanding Role of Mass Spectrometry in Biotechnology (2nd Edition). MCC Press, CA, USA (2006).
31. Finehout EJ, Franck Z, Lee KH. Complement protein isoforms in CSF as possible biomarkers for neurodegenerative disease. Dis. Markers 21, 93-101 (2005). (Pubitemid 40875153)
32. Yin GN, Lee HW, Cho JY, Suk K. Neuronal pentraxin receptor in cerebrospinal fluid as a potential biomarker for neurodegenerative diseases. Brain Res. 1265, 158-170 (2009).
33. Jung SM, Lee K, Lee J et al. Both plasma retinol-binding protein and haptoglobin precursor allele 1 in CSF: candidate biomarkers for the progression of normal to mild cognitive impairment to Alzheimers disease. Neurosci. Lett. 436, 153-157 (2008).
34. Finehout EJ, Franck Z, Choe LH, Relkin N, Lee KH. Cerebrospinal fluid proteomic biomarkers for Alzheimers disease. Ann. Neurol. 61, 120-129 (2007). (Pubitemid 46363839)
35. Korolainen MA, Nyman TA, Nyyssonen P, Hartikainen ES, Pirttila T. Multiplexed proteomic analysis of oxidation and concentrations of cerebrospinal fluid proteins in Alzheimer disease. Clin. Chem. 53, 657-665 (2007). (Pubitemid 46580235)
36. Biroccio A, del Boccio P, Panella M et al. Differential post-translational modifications of tansthyretin in Alzheimers disease: a study of the cerebral spinal fluid. Proteomics 6, 2305-2313 (2006).
37. Portelius E, Zetterberg H, Andreasson U et al. An Alzheimers disease-specific b-amyloid fragment signature in cerebrospinal fluid. Neurosci. Lett. 409, 215-219 (2006). (Pubitemid 44648565)
38. Selle H, Lamerz J, Buerger K et al. Identification of novel biomarker candidates by differential peptidomics analysis of cerebrospinal fluid in Alzheimers disease. Comb. Chem. High Throughput Screen. 8, 801-806 (2005). (Pubitemid 41771581)
39. Matsumoto A, Matsumoto R, Kadoyama K, Nishimoto T, Matsuyama S, Midorikawa O. Quantitative analysis of b-amyloid peptides expressed in human cerebrospinal fluid by an improved method of antibody-assisted time-of-flight mass spectrometry. Int. J. Pept. Res. Ther. 15, 205-210 (2009).
40. Simonsen AH, McGuire J, Hansson O et al. Novel panel of cerebrospinal fluid biomarkers for the prediction of progression to Alzheimer dementia in patients with mild cognitive impairment. Arch. Neurol. 64, 366-370 (2007). (Pubitemid 46425690)
41. Simonsen AH, McGuire J, Podust VN et al. A novel panel of cerebrospinal fluid biomarkers for the differential diagnosis of Alzheimers disease versus normal aging and frontotemporal dementia. Dement. Geriatr. Cogn. Disord. 24, 434-440 (2007). (Pubitemid 350175903)
42. Simonsen AH, McGuire J, Podust VN et al. Identification of a novel panel of cerebrospinal fluid biomarkers for Alzheimers disease. Neurobiol. Aging 29, 961-968 (2008). (Pubitemid 351697984)
43. Qin W, Ho L, Wang J, Peskind E, Pasinetti GM. S100A7, a novel Alzheimers disease biomarker with non-amyloidogenic a-secretase activity acts via selective promotion of ADAM-10. PLoS ONE 4, e4183 (2009).
44. Wittke S, Mischak H, Walden M, Kolch W, Radler T, Wiedemann K. Discovery of biomarkers in human urine and cerebrospinal fluid by capillary electrophoresis coupled to mass spectrometry: towards new diagnostic and therapeutic approaches. Electrophoresis 26, 1476-1487 (2005). (Pubitemid 40645466)
45. Gygi SP, Rist B, Gerber SA, Turecek F, Gelb MH, Aebersold R. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat. Biotechnol. 17, 994-999 (1999). (Pubitemid 29474856)
46. Zhang J, Goodlett DR, Quinn JF et al. Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer disease. J. Alzheimers Dis. 7, 125-133 (2005). (Pubitemid 40592186)
47. Ross PL, Huang YN, Marchese JN et al. Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol. Cell. Proteomics 3, 1154-1169 (2004).
48. Abdi F, Quinn JF, Jankovic J et al. Detection of biomarkers with a multiplex quantitative proteomics platform in cerebrospinal fluid of patients with neurodegenerative disorders. J. Alzheimers Dis. 9, 293-348 (2006). (Pubitemid 44253348)
49. Choe L, DAscenzo M, Relkin NR et al. 8-plex quantitation of changes in cerebrospinal fluid protein expression in subjects undergoing intravenous immunoglobulin treatment for Alzheimers disease. Proteomics 7, 3651-3660 (2007). (Pubitemid 350022271)
50. Portelius E, Brinkmalm G, Tran AJ, Zetterberg H, Westman-Brinkmalm A, Blennow K. Identification of novel APP/Ab isoforms in human cerebrospinal fluid. Neurodegener. Dis. 6, 87-94 (2009).
51. Pan S, Rush J, Peskind ER et al. Application of targeted quantitative proteomics analysis in human cerebrospinal fluid using a liquid chromatography matrix-assisted laser desorption/ionization time-of-flight tandem mass spectrometry (LC MALDI TOF/TOF) platform. J. Proteome Res. 7, 720-730 (2007). (Pubitemid 351294034)
52. Lange V, Picotti P, Domon B, Aebersold R. Selected reaction monitoring for quantitative proteomics: a tutorial. Mol. Syst. Biol. 4, 222 (2008).
53. Oe T, Ackermann BL, Inoue K et al. Quantitative analysis of amyloid b peptides in cerebrospinal fluid of Alzheimers disease patients by immunoaffinity purification and stable isotope dilution liquid chromatography/negative electrospray ionization tandem mass spectrometry. Rapid Commun. Mass Spectrom. 20, 3723-3735 (2006). (Pubitemid 44935325)
54. Carr SA, Anderson L. Protein quantitation through targeted mass spectrometry: the way out of biomarker purgatory? Clin. Chem. 54, 1749-1752 (2008).
55. Paulovich AG, Whiteaker JR, Hoofnagle AN, Wang P. The interface between biomarker discovery and clinical validation: the tar pit of the protein biomarker pipeline. Proteomics Clin. Appl. 2, 1386-1402 (2008).
56. Clish CB, Davidov E, Oresic M et al. Integrative biological analysis of the APOE*3-leiden transgenic mouse. OMICS 8, 3-13 (2004). (Pubitemid 38481151)
57. Ramsey SA, Gold ES, Aderem A. A systems biology approach to understanding atherosclerosis. EMBO Mol. Med. 2, 79-89 (2010).
58. Liu HB, Sadygov RG, Yates JR. A model for random sampling and estimation of relative protein abundance in shotgun proteomics. Anal. Chem. 76, 4193-4201 (2004).
59. Alzheimers Association. 2009 Alzheimers disease facts and figures www.alz.org/national/documents/ report-alzfactsfigures2009.pdf (Accessed January 2010)